ALL
Pharma in China
Pharma Experts
Market News
Products Guide
Brand Story
-
FDA Approves Camcevi (leuprolide mesylate) for the Treatment of Advanced Prostate Cancer
May 27, 2021Foresee announced today that the U.S. Food and Drug Administration (FDA) has approved the New Drug Application for Camcevi 42 mg, a ready-to-use 6-month subcutaneous depot formulation of leuprolide mesylate, as a treatment of advanced prostate cancer
Pharma Sources Insight January 2025
